Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D3S-001 in KRAS p.G12C-mutated advanced solid tumors (Phase I/II)
CTR20222546Phase 2Active
- Sponsor
- D3 Bio
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of elisrasib in Nonhematologic neoplasms (2 arms), sponsored by D3 Bio. Primary endpoints: Treatment-emergent adverse events and treatment-related adverse events and Maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). Started Feb 2023; status: active.
02
Drugs
elisrasib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20222546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222546.